Article
A first-in-class EGFR-directed KRAS G12V selective inhibitor.
Cancer cell - 13 Oct 2025
Stanland Lyla J, Huggins Hayden P, Sahoo Snehasudha S, Porrello Alessandro, Chareddy Yogitha, Azam Salma H, Perry Jillian L, Pallan Pradeep S, Whately Kristina, Edatt Lincy, Green William D, Fleming Matthew C, Im Jonah, Gutierrez-Ford Christina, Simmons Imani, Dawoud Alyaa, Zhou Katherine I, Jayaprakash Vandanaa, Sellers Rani S, Cruz Gabriela de la, Wielgus Albert, Milner Justin, Egli Martin, Bowers Albert A, Pecot Chad V
Abstract excerpt
Despite KRASG12V being the second most common KRAS mutation in cancer, no direct inhibitors targeting KRASG12V have been approved. RNA interference (RNAi) has faced numerous obstacles as cancer therapeutic, including the lack of cancer-specific tissue targeting, rapid oligonucleotide nuclease degradation, and clearance from circulation. Recently, the use of targetable ligands conjugated to chemically modified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.